Tetrandrine identified in a small molecule screen to activate mesenchymal stem cells for enhanced immunomodulation
Citations Over TimeTop 14% of 2016 papers
Abstract
Pre-treatment or priming of mesenchymal stem cells (MSC) prior to transplantation can significantly augment the immunosuppressive effect of MSC-based therapies. In this study, we screened a library of 1402 FDA-approved bioactive compounds to prime MSC. We identified tetrandrine as a potential hit that activates the secretion of prostaglandin E2 (PGE2), a potent immunosuppressive agent, by MSC. Tetrandrine increased MSC PGE2 secretion through the NF-κB/COX-2 signaling pathway. When co-cultured with mouse macrophages (RAW264.7), tetrandrine-primed MSC attenuated the level of TNF-α secreted by RAW264.7. Furthermore, systemic transplantation of primed MSC into a mouse ear skin inflammation model significantly reduced the level of TNF-α in the inflamed ear, compared to unprimed cells. Screening of small molecules to pre-condition cells prior to transplantation represents a promising strategy to boost the therapeutic potential of cell therapy.
Related Papers
- Enhancement of radiosensitivity in human glioblastoma U138MG cells by tetrandrine.(1999)
- THE CARDIOVASCULAR EFFECTS OF TETRANDRINE AND DEMETHYL-TETRANDRINE(1958)
- ANTI-SRS-A EFFECT OF TETRANDRINE(1984)
- A Study of Inhibitory Effect of Tetrandrine on Experimental Hepatic Fibrosis(2002)
- Progress of Research on Anti-tumor Effect of Tetrandrine(2008)